well if they only mention of iplex is the $11.5 from shire then I hope somebody ask more about it - let's see.....merck bought both facilities to ever make iplex - ipsen iclrelex not worth a #$%$ Shire for premacure(and that's all they want it for = BS) - and let's see....no mention of ALS, Oncolgy, or any other indication that iplex could be used for and is superior to increlex. Oh yea - all of a sudden Bristol Meyers is rumored to buy out Shire after they finally go their hands on iplex!!
any of us longs are not that stupid to say iplex will be monetized in 2018 - they have the big pahrmas with the grips on the patent dispute by their #$%$ with the 99% pure form with a different way to manufacture with a different trademark.......connect the dots!!!
So, iplex and its patents should be considered worthless assets?? Was Arikace or amikacin and its related patents and formulations considered a worthless asset 4 years ago even though it was in the pipeline as a possible drug therapy? Correct me if I'm wrong, but I think amikacin and iplex were FDA approved for some form of treatments.
Not sure why one would be considered in the pipeline, and the other not. What's your defition of "pipeline"? Is "pipeline" an already approved drug, or is it one that has the potential to be an approved drug?
While I would definitely agree that Arikase is the LEAD drug in the pipeline, I think Iplex has
a value that will eventually be seen. If not, why wouldn't they just sell Premicure and all
other indications when they had a chance? They only sold Iplex for ONE indication, and
retained it for all others.
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON MAY 23, 2013
NOTICE IS HEREBY GIVEN that the 2013 Annual Meeting of Shareholders of Insmed Incorporated will be held at the Hilton East
Brunswick Hotel and Executive Meeting Center, 3 Tower Center Boulevard, East Brunswick, New Jersey 08816, on May 23, 2013, at 9:00 a.m.
local time and at any adjournment or postponement thereof, for the following purposes:
1. To elect three Class I directors to serve until the 2016 Annual Meeting of Shareholders;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending
December 31, 2013;
3. To ratify and approve certain equity compensation awards previously granted to certain current and former employees and
directors under our 2000 Stock Incentive Plan;
4. To approve the Insmed Incorporated 2013 Incentive Plan; and
5. To transact such other business as may properly come before the meeting.
Holders of record of shares of Insmed common stock at the close of business on March 28, 2013, will be entitled to vote at the Annual